Clinical Trial

A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102/SHR-9839(sc) with Adebrelimab with or without other Antitumor Therapy in Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. To explore the reasonable dosage of SHR-A2102/SHR-9839（sc） for Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-07-01; most recent amendment 2026-07-16.
Status change: Not Yet Recruiting → Recruiting 2025-07-21
Trial Details
NCT Number NCT07059221
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Enrollment 210 participants
Start Date 2025-07-11
Primary Completion 2027-03 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-20